Novartis' compassionate use requests worldwide: Just 0.5% came from lower-middle- and low-income countries

Zachary Brennan

Senior Editor

From 2018 through 2020, Novartis received almost 32,000 requests from 110 countries to use one of the company’s experimental drugs (known as “compassionate use” requests …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis' compassionate use requests worldwide: Just 0.5% came from lower-middle- and low-income countries

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

NIH’s funding cut plan poses challenges for researchers despite court halt

AbbVie pens another T cell engager deal, this time with Xilio

Kaiser Permanente calls on FDA and Congress to firm up accelerated approval requirements

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

No­var­tis' com­pas­sion­ate use re­quests world­wide: Just 0.5% came from low­er-mid­dle- and low-in­come coun­tries

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis' compassionate use requests worldwide: Just 0.5% came from lower-middle- and low-income countries